Samsung takes first step into biosimilars through Quintiles joint venture
This article was originally published in Scrip
Executive Summary
Samsung is to set up a Won300 billion ($265 million) joint venture with Quintiles Transnational for the contract manufacture of biopharmaceuticals that will also eventually make biosimilar and original biologic products developed by the diversified South Korean conglomerate.